

WEST Search History

DATE: Monday, March 04, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
L7	human adj50 dual specificity phosphatase	12	L7
	<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>		
L6	L5	47	L6
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
L5	dual specificity phosphatase	47	L5
	<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>		
L4	dual specifcity phosphatase	0	L4
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
L3	('6258582')[PN]	1	L3
L2	('6132964')[PN]	1	L2
L1	('6268135')[PN]	1	L1

END OF SEARCH HISTORY

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 12 returned.**☐ 1. Document ID: US 6335170 B1

L7: Entry 1 of 12

File: USPT

Jan 1, 2002

US-PAT-NO: 6335170

DOCUMENT-IDENTIFIER: US 6335170 B1

TITLE: Gene expression in bladder tumors

DATE-ISSUED: January 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Orntoft; Torben F.	DK 8230 Aabyhoj			DKX

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2, 536/23.1, 536/24.3, 536/24.31, 536/24.33

ABSTRACT:

Methods for analyzing tumor cells, particularly bladder tumor cells employ gene expression analysis of samples. Gene expression patterns are formed and compared to reference patterns. Alternatively gene expression patterns are manipulated to exclude genes which are expressed in contaminating cell populations. Another alternative employs subtraction of the expression of genes which are expressed in contaminating cell types. These methods provide improved accuracy as well as alternative basis for analysis from diagnostic and prognostic tools currently available.

21 Claims, 24 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 2. Document ID: US 6331614 B1

L7: Entry 2 of 12

File: USPT

Dec 18, 2001

US-PAT-NO: 6331614

DOCUMENT-IDENTIFIER: US 6331614 B1

TITLE: Human CDC14A gene

DATE-ISSUED: December 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wong; Alexander K. C.	La Jolla	CA		
Teng; David H. -F.	Salt Lake City	UT		
Tavtigian; Sean V.	Salt Lake City	UT		

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 536/23.1

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to human CDC14A gene which has been found to be mutated in certain tumor cell lines. More specifically, the invention relates to a novel sequence for the human CDC14A gene. The present invention further relates to somatic mutations in the CDC14A gene in human cancer and their use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the CDC14A gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the CDC14A gene for mutations, which are useful for diagnosing the predisposition to cancer.

14 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 3. Document ID: US 6331396 B1

L7: Entry 3 of 12

File: USPT

Dec 18, 2001

US-PAT-NO: 6331396

DOCUMENT-IDENTIFIER: US 6331396 B1

TITLE: Arrays for identifying agents which mimic or inhibit the activity of interferons

DATE-ISSUED: December 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Silverman; Robert H.	Beachwood	OH		
Williams; Bryan R. G.	Cleveland	OH		
Der; Sandy	Cleveland	OH		

US-CL-CURRENT: 435/6; 435/287.2, 536/23.1, 536/23.52, 536/24.3, 536/24.31

ABSTRACT:

Methods and model systems for identifying and characterizing new therapeutic agents, particularly proteins, which mimic or inhibit the activity of all interferons, Type I interferons, IFN-.alpha., IFN-.beta., or IFN-.gamma.. The method comprises administering an interferon selected from the group consisting of IFN-.alpha., IFN-.beta., IFN-.tau., IFN-.omega., IFN-.gamma., and combinations thereof to cultured cells, administering the candidate agent to a duplicate culture of cells; and measuring the effect of the candidate agent and the interferon on the transcription or translation of one or, preferably, a plurality of the interferon stimulated genes or the interferon repressed genes (hereinafter referred to as "ISG's" and "IRGs", respectively). The model system is an array with gene probes that hybridize with from about 100 to about 5000 ISG and IRG transcripts.

8 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	-----------	-------

☐ 4. Document ID: US 6268135 B1

L7: Entry 4 of 12

File: USPT

Jul 31, 2001

US-PAT-NO: 6268135

DOCUMENT-IDENTIFIER: US 6268135 B1

TITLE: Phospholipase molecule and uses therefor

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Acton; Susan	Lexington	MA		

US-CL-CURRENT: 435/6; 435/198, 435/21, 435/252.3, 435/320.1, 530/350, 536/23.2, 536/23.5

ABSTRACT:

Novel CSAPL polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length CSAPL proteins, the invention further provides isolated CSAPL fusion proteins, antigenic peptides and anti-CSAPL antibodies. The invention also provides CSAPL nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CSAPL gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

14 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 5. Document ID: US 6258582 B1

L7: Entry 5 of 12

File: USPT

Jul 10, 2001

US-PAT-NO: 6258582

DOCUMENT-IDENTIFIER: US 6258582 B1

TITLE: CSAPTP nucleic acid molecules and uses therefor

DATE-ISSUED: July 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Acton; Susan	Jamaica Plain	MA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/69.1, 530/350, 536/23.2, 536/23.5

ABSTRACT:

Novel CSAPTP polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length CSAPTP proteins, the invention further provides isolated CSAPTP fusion proteins, antigenic peptides and anti-CSAPTP antibodies. The invention also provides CSAPTP nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CSAPTP gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

23 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 6. Document ID: US 6162897 A

L7: Entry 6 of 12

File: USPT

Dec 19, 2000

US-PAT-NO: 6162897

DOCUMENT-IDENTIFIER: US 6162897 A

TITLE: 17q-linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: December 19, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Mark H.	Salt Lake City	UT		
Goldgar; David E.	Salt Lake City	UT		
Miki; Yoshio	Salt Lake City	UT		
Swenson; Jeff	Salt Lake City	UT		
Kamb; Alexander	Salt Lake City	UT		
Harshman; Keith D.	Salt Lake City	UT		
Shattuck-Eidens; Donna M.	Salt Lake City	UT		
Tavtigian; Sean V.	Salt Lake City	UT		
Wiseman; Roger W.	Durham	NC		
Futreal; P. Andrew	Durham	NC		

US-CL-CURRENT: 530/350; 424/174.1, 435/7.1

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

3 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 7. Document ID: US 6074851 A

L7: Entry 7 of 12

File: USPT

Jun 13, 2000

US-PAT-NO: 6074851

DOCUMENT-IDENTIFIER: US 6074851 A

TITLE: Catalytic macro molecules having cdc25B like activity

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deibel, Jr.; Martin R.	Kalamazoo	MI		
Yem; Anthony W.	Kalamazoo	MI		
Wolfe; Cindy L.	Portage	MI		

US-CL-CURRENT: 435/69.7; 435/194

ABSTRACT:

This invention discloses novel forms of catalytic macro molecules that are related to cdc25B, a

cell cycle specific phosphatase. These special domains of cdc25B, special fusions with GST, and unique peptides and proteins, their utility, and the method of making them are all described.

3 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 8. Document ID: US 5998188 A

L7: Entry 8 of 12

File: USPT

Dec 7, 1999

US-PAT-NO: 5998188
DOCUMENT-IDENTIFIER: US 5998188 A

TITLE: Mitogen activated protein kinase phosphatase cDNAs and their biologically active expression products

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stork; Philip J. S.	Portland	OR		
Misra-Press; Anita	Portland	OR		

US-CL-CURRENT: 435/196

ABSTRACT:

The invention relates to a novel mitogen-activated protein kinase phosphatase, MKP-2. The invention further relates to methods and means for preparing and to nucleic acids encoding this protein. The MKP-2 of the present invention is useful in the control of cell growth, differentiation and apoptosis.

3 Claims, 44 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 24

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 9. Document ID: US 5753441 A

L7: Entry 9 of 12

File: USPT

May 19, 1998

US-PAT-NO: 5753441
DOCUMENT-IDENTIFIER: US 5753441 A

TITLE: 170-linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: May 19, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Mark H.	Salt Lake City	UT		
Goldgar; David E.	Salt Lake City	UT		
Miki; Yoshio	Salt Lake City	UT		
Swenson; Jeff	Salt Lake City	UT		
Kamb; Alexander	Salt Lake City	UT		
Harshman; Keith D.	Salt Lake City	UT		
Shattuck-Eidens; Donna M.	Salt Lake City	UT		
Tavtigian; Sean V.	Salt Lake City	UT		
Wiseman; Roger W.	Durham	NC		
Futreal; P. Andrew	Durham	NC		

US-CL-CURRENT: 435/6, 424/1.11, 435/4, 435/7.1, 435/7.2, 435/7.9, 435/91.1, 435/91.2, 436/500, 436/548, 530/387.2, 530/388.1, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

37 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 10. Document ID: US 5710001 A

L7: Entry 10 of 12

File: USPT

Jan 20, 1998

US-PAT-NO: 5710001

DOCUMENT-IDENTIFIER: US 5710001 A

TITLE: 17q-linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: January 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Mark H.	Salt Lake City	UT		
Goldgar; David E.	Salt Lake City	UT		
Miki; Yoshio	Salt Lake City	UT		
Swenson; Jeff	Salt Lake City	UT		
Kamb; Alexander	Salt Lake City	UT		
Harshman; Keith D.	Salt Lake City	UT		
Shattuck-Eidens; Donna M.	Salt Lake City	UT		
Tavtigian; Sean V.	Salt Lake City	UT		
Wiseman; Roger W.	Durham	NC		
Futreal; P. Andrew	Durham	NC		

US-CL-CURRENT: 435/6; 435/7.1, 435/7.9, 435/91.2, 530/300, 530/350, 530/388.1, 536/23.1,
536/24.3, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

35 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

[Generate Collection](#)[Print](#)

Terms	Documents
human adj50 dual specificity phosphatase	12

Display Format:

REV

[Change Format](#)[Previous Page](#)[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 12 of 12 returned.**☐ 11. Document ID: US 5709999 A

L7: Entry 11 of 12

File: USPT

Jan 20, 1998

US-PAT-NO: 5709999

DOCUMENT-IDENTIFIER: US 5709999 A

TITLE: Linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: January 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shattuck-Eidens; Donna M.	Salt Lake City	UT		
Simard; Jacques	St. Augustin de Desmaures			CAX
Durocher; Francine	Ste-Foy			CAX
Emi; Mitsuuru	Tokyo			JPX
Nakamura; Yusuke	Yokohama			JPX

US-CL-CURRENT: 435/6; 435/91.2, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

35 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 12. Document ID: US 5573935 A

L7: Entry 12 of 12

File: USPT

Nov 12, 1996

US-PAT-NO: 5573935

DOCUMENT-IDENTIFIER: US 5573935 A

TITLE: Protein tyrosine kinase A6

DATE-ISSUED: November 12, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beeler; John F.	Bethesda	MD		
Larochelle; William	Gaithersburg	MD		
Aaronson; Stuart A.	Great Falls	VA		

US-CL-CURRENT: 435/194; 435/252.3, 435/252.33, 435/320.1, 435/69.8, 536/23.2, 536/23.5, 930/240

ABSTRACT:

A novel protein tyrosine kinase (A6) exhibiting no significant similarity to any known kinase. This protein is widely expressed throughout the body and is present in a variety of vertebrates. The cDNA was expressed in bacteria as a fusion protein which was both autophosphorylated and exhibited kinase activity toward exogenous substrates. Potential uses of this invention include immunodiagnostics and antiproliferative therapeutics.

10 Claims, 1 Drawing figures

Exemplary Claim Number: 1,9

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

[Generate Collection](#)[Print](#)**Terms****Documents**

human adj50 dual specificity phosphatase

12

Display Format: [REV](#)[Change Format](#)[Previous Page](#)[Next Page](#)